Search Contract Opportunities

VISN IDIQ LENALIDOMIDE Sole Source Justification

ID: 36C24226F0064 • Type: Special Notice • Match:  90%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Popular Questions:
Generate a draft:
Loading

Description

This is a notice of intent to award a Sole-Source only contract and is not a request for quotes. Name of Proposed Contractor Exelan Pharmaceuticals Street Address: 370 W. Camino Gardens, Suite 204 City, State, Zip: Boca Raton, FL 334432 The objective of this action is the procurement for: The purpose of this contract is to establish a reliable and continuous supply of Lenalidomide, an immunomodulatory drug used primarily to treat multiple myeloma, anemia in myelodysplastic syndromes (MDS) in adults, and certain types of lymphoma. Lenalidomide works by enhancing the immune system s ability to fight cancer cells. It inhibits the growth of new blood vessels in tumors and alters the immune response to target and destroy malignant cells. It comes with serious risks that require careful management and monitoring. Contractor shall provide all materials, labor, and equipment necessary to supply Lenalidomide in accordance with all applicable federal regulations, Good Manufacturing Practices (cGMP) and the Food and Drug Administration (FDA) requirements. This is an emergent need to ensure continuous supply, to meet regulatory obligations (Risk Evaluation and Mitigation Strategy REMS) program, and to support patient access.
Background
The Department of Veterans Affairs is issuing a sole-source contract to Exelan Pharmaceuticals, located at 370 W. Camino Gardens, Suite 204, Boca Raton, FL 33443. The objective of this action is to procure a reliable and continuous supply of Lenalidomide, an immunomodulatory drug primarily used to treat multiple myeloma, anemia in myelodysplastic syndromes (MDS) in adults, and certain types of lymphoma.

Lenalidomide enhances the immune system's ability to fight cancer cells and requires careful management due to serious risks associated with its use.

Work Details
The contractor shall provide all materials, labor, and equipment necessary to supply Lenalidomide in accordance with all applicable federal regulations, Good Manufacturing Practices (cGMP), and Food and Drug Administration (FDA) requirements.

This contract addresses an emergent need to ensure continuous supply and compliance with regulatory obligations under the Risk Evaluation and Mitigation Strategy (REMS) program to support patient access.

Overview

Response Deadline
May 19, 2026, 4:00 p.m. EDT Past Due
Posted
May 5, 2026, 10:42 a.m. EDT
Set Aside
None
Place of Performance
Not Provided
Source

Current SBA Size Standard
1300 Employees
Pricing
Likely Fixed Price
Est. Level of Competition
Sole Source
Est. Value Range
Experimental
$250,000 - $1,500,000 (AI estimate)
Vehicle Type
Indefinite Delivery Contract
On 5/5/26 VISN 2: New York/New Jersey VA Health Care Network issued Special Notice 36C24226F0064 for VISN IDIQ LENALIDOMIDE Sole Source Justification due 5/19/26.
Primary Contact
Title
Contract Specialist
Name
Corey Swinton   Profile
Phone
None

Documents

Posted documents for Special Notice 36C24226F0064

Opportunity Assistant


AI Analysis

AI Generate

Incumbent or Similar Awards

Contracts Similar to Special Notice 36C24226F0064

Potential Bidders and Partners

Awardees that have won contracts similar to Special Notice 36C24226F0064

Similar Active Opportunities

Open contract opportunities similar to Special Notice 36C24226F0064

Experts for VISN IDIQ LENALIDOMIDE Sole Source Justification

Recommended subject matter experts available for hire

Additional Details

Source Agency Hierarchy
VETERANS AFFAIRS, DEPARTMENT OF > VETERANS AFFAIRS, DEPARTMENT OF > 242-NETWORK CONTRACT OFFICE 02 (36C242)
FPDS Organization Code
3600-00242
Source Organization Code
100186522
Last Updated
May 5, 2026
Last Updated By
corey.swinton@va.gov
Archive Date
Aug. 26, 2026